Granicip 1 mg, 2 mg FC tablets.
PDF Leaflet Revision Date: 29 May 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of acute and delayed nausea and vomiting associated with chemotherapy and radiotherapy.
Dosage (summary)
1 mg twice daily or 2 mg once daily for up to one week post-chemotherapy; 2 mg once daily for up to one week post-radiotherapy.
Onset of Action / Duration
Onset: 1 hour before therapy, Duration: up to 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy and lactation due to safety concerns.
Key Drug Interactions
- Serotonergic medicines
- Buprenorphine/opioids
- Phenobarbitone
- Ketoconazole
Contraindications
- Hypersensitivity to granisetron
- Children under 2 years
- Congenital long QT syndrome
Common side effects
- Headache
- Constipation
- Dizziness
- Fatigue
- QT interval prolongation
Counselling Points
- Monitor for signs of serotonin syndrome
- Avoid driving until effects are known
- Do not exceed maximum dose of 9 mg in 24 hours
Serious warnings
- Risk of myocardial ischemia
- QT prolongation
- Serotonin syndrome
Important Disclaimer
The Granicip 1 mg, 2 mg FC tablets. professional information leaflet below is the property of Cipla Medpro and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
